43.76 +0.55 (1.27%)
Pre-Market: 6:51AM EST
|Bid||43.69 x 800|
|Ask||43.33 x 1100|
|Day's Range||42.90 - 43.22|
|52 Week Range||35.39 - 48.93|
|Beta (3Y Monthly)||-0.13|
|PE Ratio (TTM)||27.11|
|Forward Dividend & Yield||0.73 (1.70%)|
|1y Target Est||52.50|
OXINIUM Technology is the first advanced bearing material available to support modular dual mobility throughout the entire offering LONDON , Nov. 8, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), ...
TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors. "On behalf of the entire board, I am delighted to welcome Roland to Accelerate Diagnostics," commented John Patience, Chairman of the Board of Directors. "Roland brings extensive experience from his decades of successful diagnostics company leadership.
A federal appeals court on Thursday said the structure of the U.S. Patent Trial and Appeal Board is unconstitutional, but the problem can be fixed by severing a portion of federal patent law that restricts the removal of administrative patent judges. The U.S. Federal Circuit Court of Appeals said the impact of its decision would be "limited" to cases in which the board had issued final written decisions, and litigants challenged on appeal the appointment of the board's judges under the U.S. Constitution's Appointments Clause.
Namal Nawana is stepping down as chief executive of Smith & Nephew less than 18 months into the role amid reports of a disagreement over pay.
European shares broke a three-day run of losses on Monday, as investors stuck to hopes that Britain will avoid a disorderly exit from the European Union, while positive corporate updates and comments on U.S.-China trade talks added to the upbeat mood. The pan-European STOXX 600 index ended the session 0.6% higher, barely budging on news House of Commons speaker John Bercow refused to allow a vote on Prime Minister Boris Johnson's Brexit divorce deal, saying the same issue had been discussed on Saturday.
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...
The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday. The SEC had alleged that Bobby Dwayne Montgomery prompted Osiris to book fake revenue and give false information to auditors. Montgomery agreed to a judgment that enjoins him from future violations of securities law, the SEC said in a statement.
We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Smith & Nephew plc (NYSE:SNN) based on […]
LONDON , Oct. 9, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce results for its NOVOSTITCH Meniscal Repair System today at the International ...
“You’re not going to find a whole lot of other funds in the Southeast that have [a musculoskeletal focus]. … And, there’s not a life sciences industry to speak of in Nashville or even Atlanta.”
Smith & Nephew plc (LON:SN.) is about to trade ex-dividend in the next 2 days. If you purchase the stock on or after...
Helps protect healthcare systems against reoperation costs for hip fractures LONDON , Sept. 26, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announced ...
The LENS 4K System features a Camera Control Unit with an integrated light source, Camera Head, image management options and Tablet Application in a single solution. The latest native 4K 3CMOS Ultra High Definition technology combined with Smith+Nephew's proprietary image and light processing is intended to create impressive color reproduction, image clarity, and depth of field.
LONDON , Sept. 10, 2019 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is pleased to announce the US launch of the new PICO 7Y Single Use Negative Pressure Wound ...
Is Smith & Nephew plc (LON:SN.) a good dividend stock? How can we tell? Dividend paying companies with growing...
Examining how Smith & Nephew plc (LON:SN.) is performing as a company requires looking at more than just a years...
Nancy Zambell, editor of Wall Street's Best Investments, chose Smith & Nephew plc (SNN) as her top conservative investment idea for 2019. The stock rose 16.5% in the first half of the year. Here's her latest update on the healthcare firm.